KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) EBT Margin (2020 - 2025)

Historic EBT Margin for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to 3135.27%.

  • Recursion Pharmaceuticals' EBT Margin fell 27684400.0% to 3135.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 1638.15%, marking a year-over-year decrease of 10506600.0%. This contributed to the annual value of 789.93% for FY2024, which is 448300.0% down from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' EBT Margin stood at 3135.27%, which was down 27684400.0% from 894.23% recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year EBT Margin high stood at 366.82% for Q3 2024, and its period low was 3935.31% during Q4 2024.
  • Its 5-year average for EBT Margin is 1267.8%, with a median of 891.18% in 2023.
  • In the last 5 years, Recursion Pharmaceuticals' EBT Margin surged by 293818100bps in 2021 and then crashed by -30441300bps in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' EBT Margin (Quarter) stood at 2564.55% in 2021, then soared by 83bps to 445.91% in 2022, then tumbled by -100bps to 891.18% in 2023, then crashed by -342bps to 3935.31% in 2024, then grew by 20bps to 3135.27% in 2025.
  • Its EBT Margin stands at 3135.27% for Q3 2025, versus 894.23% for Q2 2025 and 1374.33% for Q1 2025.